UK markets closed

Spero Therapeutics, Inc. (SPRO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.4700+0.0400 (+2.80%)
As of 01:58PM EDT. Market open.
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
17,667
96,735
48,579
3,070
258
Operating expenses
Research development
49,729
51,440
47,593
64,526
67,003
Selling general and administrative
43,009
25,554
36,483
41,701
21,440
Total operating expenses
101,593
69,948
79,146
91,041
79,371
Operating income or loss
-83,926
26,787
-30,567
-87,971
-79,113
Interest expense
4,545
0
2,605
1,940
0
Total other income/expenses net
-14,422
-5,320
-14,349
-191
432
Income before tax
-102,426
25,404
-46,415
-89,756
-78,280
Income tax expense
2,598
2,598
0
-
-
Income from continuing operations
-102,426
22,806
-46,415
-89,756
-78,280
Net income
-102,426
22,806
-46,415
-89,756
-78,280
Net income available to common shareholders
-102,426
22,806
-46,415
-89,756
-78,280
Basic EPS
0.39
0.43
-1.23
-2.91
-3.52
Diluted EPS
0.39
0.43
-1.23
-2.91
-3.52
Basic average shares
51,662
52,703
37,585
30,896
22,386
Diluted average shares
51,662
52,989
37,585
30,896
22,386